Table 6.
Treatment recommendations with elbasvir–grazoprevir (EBR/GZR) for HCV genotypes 1 and 4
| Guideline | Patients | Regimen | Duration (weeks) |
|---|---|---|---|
| AASLD/IDSA | Gt 1a: TN or TE (P/R), without NS5A RASs | EBR/GZR | 12 |
| Gt 1a: TN or TE (P/R), with NS5A RASs | EBR/GZR + RBV | 16 | |
| Gt 1b: TN or TE (P/R) | EBR/GZR | 12 | |
| Gt 1a or 1b: TE (P/R/PI) | EBR/GZR + RBV | 12 | |
| Gt 4: TN | EBR/GZR | 12 | |
| Gt 4: TE (P/R) | EBR/GZR + RBV | 16 | |
| EASL | Gt 1a: TN or TE (P/R), no NS5A resistance testing, low HCV RNAa | EBR/GZR | 12 |
| Gt 1a: TN or TE (P/R), no NS5A resistance testing, high HCV RNAb | EBR/GZR + RBV | 16 | |
| Gt 1a: TN or TE (P/R), without NS5A RASs, low HCV RNAa | EBR/GZR | 12 | |
| Gt 1a: TN or TE (P/R), without NS5A RASs, high HCV RNAb | EBR/GZR | 12 | |
| Gt 1a: TN or TE, with NS5A RASs, low HCV RNAa | EBR/GZR | 12 | |
| Gt 1a: TN or TE (P/R), with NS5A RASs, high HCV RNAb | EBR/GZR + RBV or alternative treatment | 16 | |
| Gt 1b: TN or TE (P/R) | EBR/GZR | 12 | |
| Gt 4: TN | EBR/GZR | 12 | |
| Gt 4: TE (P/R), low HCV RNAa | EBR/GZR | 12 | |
| Gt 4: TE (P/R), high HCV RNAb | EBR/GZR + RBV | 16 |
Notes:
a
Low HCV RNA defined as ≤800,000 (5.9 log) IU/mL;
b
high HCV RNA defined as >800,000 (5.9 log) IU/mL.
Abbreviations: AASLD, American Association for the Study of Liver Disease; EASL, European Association for the Study of the Liver; Gt, genotype; HCV, hepatitis C virus; IDSA, Infectious Diseases Society of America; PI, protease inhibitor; P/R, PEGylated interferon and ribavirin; RASs, resistance-associated substitutions; RBV, ribavirin; TE, treatment-experienced; TN, treatment-naïve.